|
Jazz Gets Intermediate Victory in Patent Fight, Likely to Maintain Xyrem Exclusivity: Analyst
Jazz Pharmaceuticals received some positive, if minor, news in its legal battle to maintain exclusivity for its narcolepsy drug Xyrem this week when a district court denied generic-drug maker Roxane Laboratories’ request to submit additional evidence showing that Jazz’s patents are invalid.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives